Cordis wraps up Flexible Stenting deal

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Cordis has completed its acquisition of Flexible Stenting Solutions, a developer of flexible peripheral arterial, venous and biliary stents. 

The addition of Flexible Stenting Solutions’ FlexStent Self Expanding Stent System provides Cordis with the opportunity to evolve the SMART Stent platform to address needs in the treatment of peripheral artery disease, according to Bridgewater, N.J.-based Cordis. 

The FlexStent System received European CE Mark approval for the treatment of vascular disease (iliac, superficial femoral artery and popliteal) in January 2009. In the U.S., the device received 510(k) clearance by the FDA for the palliative treatment of biliary strictures associated with malignant tumors in September 2009.

The system is also being evaluated in an Investigational Device Exemption study to assess its safety and efficacy in the treatment of patients with atherosclerosis in the superficial femoral artery.